Contrarian Investors: Don’t Expect a Sudden Rebound in Valeant Pharmaceuticals Intl Inc.

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) appears to be getting cheaper by the day. Is it finally time to initiate a contrarian position?

| More on:
The Motley Fool

Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is in the midst of a transformation overhaul as its new CEO Joseph Papa looks to clean up the mess that Michael Pearson and the old management team left behind. Valeant has lost almost 97% of its value as the stock continues to fall further into the abyss. Unfortunately for many contrarian investors, the stock continued its tumble into the single digits.

It’s undervalued, but is it safe to buy shares?

Many pundits believe that Valeant is extremely undervalued and that the company could offer contrarians the opportunity for a rebound of a lifetime. Valeant owns terrific core assets, but the fire sale of non-core assets is far from over, as the management team looks to raise money to chip away at the mountain of debt.

I think Valeant is close to a bottom, but if you’re hungry for a rebound, you’ve got to be realistic. Valeant probably isn’t going to skyrocket overnight or quadruple over the next three years as some of the more bullish analysts out there believe. If you’re got a stomach for volatility and you can afford to wait five years or more, then Valeant could be an intriguing rebound play. Bill Ackman had horrible timing when he first initiated a position. And maybe his decision to dump the stock was just as poorly timed.

Valeant recently released the first real positive piece of news in a long time. The company raised its full-year adjusted EBITDA forecast, and the company is on schedule to reach its target of paying back $5 billion in debt by February 2018. This is promising news, and I believe the rally that followed was completely warranted.

Where is the stock heading from here?

The rally has since run out of steam, and Valeant appears to be picking up negative momentum again. There’s a stigma surrounding Valeant which I don’t think will go away with a new management team. The possibility of a company name change was also brought up, but would this attract investors? Or is it just a cheap trick that investors will see through?

I’m not sure, but it appears that Valeant will require a steady stream of good news to keep the stock moving higher; otherwise, in the short to medium term, I think the stock will continue to decline by default.

I’m a huge fan of the core assets owned by Valeant, and I believe they are absurdly undervalued, but I think it’ll take many years to attract investors back to the company and its new, legitimate business model.

I would recommend picking up shares in very small increments on the way down, but only if you truly believe in Joseph Papa and the new management team. I think he’s the right man for the job, but keep in mind, he’s not a miracle worker. There’s still a lot of cleaning up to do, and a sustainable rally may be a year or more away.

Stay smart. Stay hungry. Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Joey Frenette has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

CPP Insights: The Average Benefit at Age 60 in 2024

The average CPP benefit at age 60 in average is low, but claiming early has many advantages with the right…

Read more »

edit Sale sign, value, discount
Investing

2 Bargains I’d Buy as They Dip Toward 52-Week Lows

Spin Master (TSX:TOY) stock and another underrated Canadian play could surge again as they look to reverse course.

Read more »

thinking
Dividend Stocks

Why Did goeasy Stock Jump 6% This Week?

The spring budget came in from our federal government, and goeasy stock (TSX:GSY) investors were incredibly pleased by the results.

Read more »

woman analyze data
Dividend Stocks

My Top 5 Dividend Stocks for Passive-Income Investors to Buy in April 2024

These five TSX dividend stocks can help you create a passive stream of dividend income for life. Let's see why.

Read more »

investment research
Stocks for Beginners

New Investors: 5 Top Canadian Stocks for 2024

Here are five Canadian stocks that might be ideal for a beginner investment portfolio.

Read more »

Pipeline
Energy Stocks

Here Is Why Enbridge Is a No-Brainer Dividend Stock

For investors looking for a no-brainer dividend stock worth holding for the long term, here's why Enbridge (TSX:ENB) should be…

Read more »

Dots over the earth connecting the world
Tech Stocks

Hot Takeaway: Concentration in 1 Stock Can Be Just Fine

Concentration in one stock can be alright under the right circumstances, and far better than buying a bunch of poor-performing…

Read more »

grow money, wealth build
Bank Stocks

TD Bank Stock Got Upgraded, and It’s a Good Time to Load Up

TD Bank (TSX:TD) stock is getting too cheap, even for analysts at the competing banks!

Read more »